716 related articles for article (PubMed ID: 34379511)
21. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
22. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
[TBL] [Abstract][Full Text] [Related]
23. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
24. Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
Sia ZR; Chiem K; Huang WC; Seffouh A; Teimouri Dereshgi A; Hogan T; Ortega J; Davidson BA; Martinez-Sobrido L; Lovell JF
J Virol; 2022 Oct; 96(19):e0100622. PubMed ID: 36106872
[TBL] [Abstract][Full Text] [Related]
25. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
[TBL] [Abstract][Full Text] [Related]
26. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
27. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
28. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
[TBL] [Abstract][Full Text] [Related]
29. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.
Rajão DS; Chen H; Perez DR; Sandbulte MR; Gauger PC; Loving CL; Shanks GD; Vincent A
J Gen Virol; 2016 Jul; 97(7):1489-1499. PubMed ID: 27031847
[TBL] [Abstract][Full Text] [Related]
30. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
Rijal P; Wang BB; Tan TK; Schimanski L; Janesch P; Dong T; McCauley JW; Daniels RS; Townsend AR; Huang KA
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748388
[TBL] [Abstract][Full Text] [Related]
31. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
[TBL] [Abstract][Full Text] [Related]
32. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
33. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
34. Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.
Thomas M; Wang Z; Sreenivasan CC; Hause BM; Gourapura J Renukaradhya ; Li F; Francis DH; Kaushik RS; Khatri M
Vaccine; 2015 Jan; 33(4):542-8. PubMed ID: 25437101
[TBL] [Abstract][Full Text] [Related]
35. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
[TBL] [Abstract][Full Text] [Related]
36. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
[TBL] [Abstract][Full Text] [Related]
37. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
38. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
39. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
[TBL] [Abstract][Full Text] [Related]
40. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
